去甲基化治疗的急性髓系白血病患者血清25-羟维生素D_(3)水平与预后的关系  

Relationship between serum 25-hydroxyvitamin D_(3) level and prognosis in acute myeloid leukemia patients treated with demethylation therapy

作　　者：柳萍[1] 陈梦醒 吴品[1] LIU Ping;CHEN Mengxing;WU Pin(Department of Hematology,Wuxi No.2 People's Hospital,Wuxi 214000,CHINA)

机构地区：[1]无锡市第二人民医院血液科,江苏214000

出　　处：《江苏医药》2024年第12期1225-1227,1233,共4页Jiangsu Medical Journal

摘　　要：目的 探讨去甲基化治疗的急性髓系白血病(AML)患者血清25-羟维生素D_(3)[25-(OH)D_(3)]水平与预后的关系。方法 118例AML患者接受阿扎胞苷和/或维奈克拉联合化疗,连续治疗10~28d。118例治疗前检测血清25-(OH)D_(3)水平,其中77例血清25-(OH)D_(3)水平低下(低下组),41例血清25-(OH)D_(3)水平正常(正常组),收集两组患者一般资料。对患者随访0.5~54个月,绘制生存曲线,分析两组患者的预后。结果 低下组与正常组性别构成比、≥65岁比例及治疗前WBC、骨髓原始细胞比例和外周血原始细胞比例均无统计学差异(P>0.05)。低下组与正常组完全缓解率比较无统计学差异(76.6%vs.78.0%)(P>0.05)。低下组和正常组2年无复发生存率分别为36.8%和15.1%,2年生存率分别为47.2%和53.6%,两组比较均无统计学差异(P>0.05)。结论 接受去甲基化治疗的AML患者血清25-(OH)D_(3)水平可能与预后无关。Objective To investigate the relationship between serum 25-hydroxyvitamin D_(3) [25-(OH)D_3] level and the prognosis in acute myeloid leukemia(AML) patients treated with demethylation therapy.Methods A total of 118 AML patients received azacitidine and/or venclexta combined chemotherapy for 10-28 days.Serum 25-(OH)D_(3) level was detected before treatment,which showed that 77 patients had low serum 25-(OH)D_(3) level(low group) and 41 patients had normal serum 25-(OH) D_(3) level(normal group).The general data of the two groups were collected.The patients were followed up for 0.5-54 months.The survival curve was drawn and the prognosis of the two groups was analyzed.Results There were no significant differences in gender ratio,proportion of more than 65 years old,WBC,bone marrow original cell ratio and peripheral blood original cell ratio before treatment between low group and normal group(P>0.05).There was no statistical difference in the complete remission rate between low group and normal group(76.6% vs.78.0%)(P>0.05).The 2-year recurrence-free survival rates of low group and normal group were 36.8% and 15.1%,and the 2-year survival rates were 47.2% and 53.6%,respectively,which were no statistical differences between the two groups(P>0.05).Conclusion The serum 25-(OH)D_(3) level is not associated with the prognosis of AML patients treated with demethylation therapy.

关 键 词：急性髓系白血病 25-羟维生素D_(3) 去甲基化治疗 

分 类 号：R551[医药卫生—血液循环系统疾病]